22. The oHSV of claim 18, wherein the transgene encodes a protein or polypeptide that induces patient immune response against the cancer.

23. The oHSV of claim 18, wherein the transgene encodes a protein or polypeptide that catalyzes the conversion of a prodrug.

24. The oHSV of claim 23, wherein the transgene encodes cytosine deaminase or thymidine kinase.

25. The oHSV of claim 18, wherein the transgene encodes purine nucleoside phosphorylase (PNP).

26. The oHSV of claim 1, which is KGE-4:T124.

27. A nucleic acid encoding the oHSV of any of claims 1-26.

28. The nucleic acid of claim 27, which is a bacterial artificial chromosome (BAC).

29. A viral stock comprising the oHSV vector of any of claims 1-26.

30. A composition comprising the oHSV of any of claims 1-26 and a pharmaceutically-acceptable carrier.

31. A composition comprising the viral stock of claim 29 and a pharmaceutically-acceptable carrier.

32. A method of killing a cancerous cell, comprising exposing the cell to the oHSV of any of claims 1-26, the stock of claim 29, or the composition of claim 30 or 31 under conditions sufficient for said oHSV to infect said cancerous cell, whereby replication of the oHSV within the cancerous cell results in cell death.

33. The method of claim 32 wherein the cell is *in vivo*.

34. The method of claim 32 or 33, wherein the cell is within a tumor.

35. The method of claim 34, wherein the tumor is glioblastoma multiforme.

36. The method of any of claims 32-35, wherein the cell is human.

37. The method of claim 34 or 35, wherein the tumor is within the brain of an animal.

38. The method of claim 37, wherein the oHSV is exposed to the cell by intracranially injecting the oHSV, stock, or composition to the animal.

39. The method of claim 38, wherein the animal is human.